Skip to main content
. 2021 Jun 9;596(7871):268–272. doi: 10.1038/s41586-021-03681-2

Fig. 3. Cellular immune responses to SARS-CoV-2 variants.

Fig. 3

a, Spike-specific pooled peptide IFNγ ELISPOT responses against WA1/2020, B.1.351, B.1.1.7, P.1 and CAL.20C. n = 25 independent samples (5 placebo recipients, 20 Ad26.COV2.S vaccine recipients). PBMC, peripheral blood mononuclear cells. b, Spike-specific pooled peptide IFNγ CD4+ and CD8+ T cell responses by ICS assays against WA1/2020, B.1.351, B.1.1.7, P.1 and CAL.20C. SFC, spot-forming cells. Responses are shown on days 57 and 85. Red bars reflect median responses. Dotted lines reflect lower limits of quantification. Filled squares denote placebo–placebo; filled circles denote high dose–placebo; open circles denote high dose–high dose; filled triangles denote low dose–placebo; and open triangles denote low dose–low dose. n = 20 independent samples from Ad26.COV2.S vaccine recipients.